At last week’s American Chemical Society Spring meeting, Bristol Myers Squibb Co. discussed the development of a potent, orally bioavailable and highly selective cereblon (CRBN)-mediated ligand-directed degrader (LDD) of B-cell lymphoma 6 protein (BCL6), BMS-986458, for the treatment of B-cell non-Hodgkin lymphoma.
Artiva Biotherapeutics Inc. raised $167 million through an upsized IPO, with funds aimed at the development of its lead AlloNK program for systemic lupus erythematosus and other autoimmune indications. Just a few days ago, the San Diego based company had aimed to sell 8.4 million shares between $14 and $16 each, but it raised the number of shares offered to 13.92 million and lowered the price to $12 each. The upsize brings Artiva’s shares outstanding following the IPO to about 22.8 million, giving the company a market cap of $273.6 million based on the IPO price.
With an IND filing in systemic lupus erythematosus expected during the third quarter of 2024, Cullinan Therapeutics Inc. changed its name from Cullinan Oncology Inc. and detailed its plans to target autoimmune diseases with CLN-978, a CD19xCD3 T-cell engager.
Verismo Therapeutics Inc. has submitted an IND application to the FDA seeking to initiate a phase I trial this year of Synkir-310 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas (B-cell NHL), including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma.
Tarapeutics Science Inc. has identified phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease (COPD) and systemic lupus erythematosus.
Hangzhou Qihan Biotech Co. Ltd. has received clinical trial clearance from China’s National Medical Products Administration (NMPA) for QN-019a for CD19-positive relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Researchers from Innate Pharma SA recently presented preclinical data for IPH-6501, a novel CD20-targeting tetraspecific antibody-based natural killer (NK)-cell engager therapeutic being developed for the treatment of patients with B-cell non-Hodgkin lymphoma (B-NHL).
C4x Discovery Holdings plc has announced further progress in its MALT1 inhibitor program for cancer. Building on anti-cancer activity in a preclinical xenograft study, the company completed a preclinical study demonstrating its MALT1 lead compounds were free of UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) liability shown by competitor chemistries. The program is continuing to identify a shortlist of preclinical candidates for further development, and a partnering program has been initiated.
The FDA has cleared Cullinan Oncology Inc.'s IND application for CLN-978, a CD19/CD3 T-cell engaging antibody construct with a human serum albumin (HSA) binding domain to increase serum half-life.